Articles by Louise M. Perkins, Ph.D., MRA Chief Science Officer


Maintaining the Pace of Melanoma Innovation in the Era of an Evolving Standard of Care

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 August 2018 In Science, Treatment

There is no doubt that treatments for metastatic melanoma have changed dramatically in the decade since MRA’s founding in 2007. How do we keep up the momentum?

Read More


FDA Approves Nivolumab in Adjuvant Setting - Is it a Big Deal?

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 21 December 2017 In News, Science, Treatment

The US FDA approved the use of nivolumab (Opdivo) in the adjuvant setting on December 20, 2017. This means that nivolumab may be used to treat melanoma patients with lymph node involvement or metastatic disease after complete surgical resection to reduce the risk of their disease recurring.

Read More


‘Practice Changing’ Results Hint at New Adjuvant Therapy Treatment Options

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 September 2017 In Treatment

Adjuvant treatment is used in addition to tumor removal e.g. via surgery or radiotherapy to help delay or prevent the recurrence of melanoma. It is often recommended for high-risk melanoma (defined as melanoma deeper or thicker than 4mm thick at the primary site or involves nearby lymph nodes). Approved adjuvant therapies in melanoma include interferon and, more recently, ipilimumab. But neither of these approaches is wholly satisfying since relatively few patients appear to benefit and side-effects are a major factor.

Read More


Melanoma Treatments: Breakthroughs for Multiple Cancers — for Real and Right Now

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 July 2017 In Science, Treatment

While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?

Read More

About the Author
Louise M. Perkins, Ph.D., MRA Chief Science Officer


MRA Chief Science Officer

Login

×